Fig. 2From: Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritisImpact of enthesitis or dactylitis resolution at week 24. Data are from integrated analysis sets of patients with baseline enthesitis and dactylitis. LS mean change from baseline (SE) of EQ-5D VAS (a) and HAQ-DI (b) scores in patients with enthesitis or dactylitis resolution. c Percentages of patients (NRI) with enthesitis or dactylitis resolution reporting improvement meeting or exceeding the MCID of the HAQ-DI (≥ 0.35). d Mean change from baseline (LOCF) (SD) of pain VAS. Only one side of the error bar is shown. Abbreviations: EQ-5D VAS, EuroQol-5 Dimensions Visual Analogue Scale; HAQ-DI, Health Assessment Questionnaire-Disability Index; LDI-B, Leeds Dactylitis Index-Basic; LEI, Leeds Enthesitis Index; LOCF, last observation carried forward; LSM, least squares mean; MCID, minimal clinically important difference; N, population size; n, number in group; NRI, nonresponder imputation; SD, standard deviation; SE, standard error; VAS, visual analogue scaleBack to article page